- Home
- STRR vs XBIO Comparison
STRR vs XBIO Comparison
Compare STRR & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRR
- XBIO
- Stock Information
- Founded
- STRR 1985
- XBIO N/A
- Country
- STRR United States
- XBIO United States
- Employees
- STRR N/A
- XBIO N/A
- Industry
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- STRR Health Care
- XBIO Health Care
- Exchange
- STRR Nasdaq
- XBIO Nasdaq
- Market Cap
- STRR 6.3M
- XBIO 5.8M
- IPO Year
- STRR N/A
- XBIO N/A
- Fundamental
- Price
- STRR $1.99
- XBIO $2.72
- Analyst Decision
- STRR
- XBIO Hold
- Analyst Count
- STRR 0
- XBIO 1
- Target Price
- STRR N/A
- XBIO N/A
- AVG Volume (30 Days)
- STRR 13.4K
- XBIO 9.9K
- Earning Date
- STRR 05-19-2025
- XBIO 05-08-2025
- Dividend Yield
- STRR N/A
- XBIO N/A
- EPS Growth
- STRR N/A
- XBIO N/A
- EPS
- STRR N/A
- XBIO N/A
- Revenue
- STRR $53,359,000.00
- XBIO $2,500,284.00
- Revenue This Year
- STRR $43.37
- XBIO $14.23
- Revenue Next Year
- STRR $23.60
- XBIO N/A
- P/E Ratio
- STRR N/A
- XBIO N/A
- Revenue Growth
- STRR 16.54
- XBIO N/A
- 52 Week Low
- STRR $1.72
- XBIO $2.20
- 52 Week High
- STRR $5.35
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- STRR 44.79
- XBIO 48.09
- Support Level
- STRR $1.72
- XBIO $2.32
- Resistance Level
- STRR $2.14
- XBIO $2.61
- Average True Range (ATR)
- STRR 0.14
- XBIO 0.15
- MACD
- STRR -0.02
- XBIO 0.07
- Stochastic Oscillator
- STRR 42.86
- XBIO 99.83
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.